Pulmonx Q2 2021 revenue $12.2M (+232% YoY); raises FY guidance to $49-51M

Pulmonx Corp

2021-Q2 EPS reported -$0.68 revenue$21,447,000

Worldwide revenue $12.2M, up 232% YoY; U.S. revenue $6.6M (+343%), international $5.6M (+157%).
Gross margin 74% vs 28% a year ago; net loss $12.4M ($0.34 per share) vs $11.9M ($6.15).
Added 20 new U.S. Zephyr Valve treating centers (total 180); launched Chartis software upgrade.
FY 2021 revenue guidance raised to $49-51M from $48-50M; OpEx unchanged at $85-90M.
Cash and marketable securities $211.5M as of June 30, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.